Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7468891 | 0.83 | MAPT (0.44) | S1PR3MAPTTP53DPP4PPARG | |
| SCHEMBL7471087 | 0.83 | L3MBTL1 (0.49) | S1PR3MAPTTP53DPP4PPARG | |
| SCHEMBL7425401 | 0.82 | MAPT (0.43) | S1PR3MAPTTP53DPP4PPARG | |
| SCHEMBL8557370 | 0.82 | TP53 (0.43) | S1PR3MAPTTP53DPP4ALDH1A1 | |
| SCHEMBL7418990 | 0.82 | MAPT (0.44) | S1PR3MAPTTP53DPP4PPARG | |
| SCHEMBL7415932 | 0.81 | MAPT (0.43) | S1PR3MAPTTP53DPP4ALDH1A1 | |
| SCHEMBL7418494 | 0.79 | MAPT (0.44) | S1PR3MAPTTP53DPP4ALDH1A1 | |
| SCHEMBL7476760 | 0.79 | MAPT (0.44) | S1PR3MAPTTP53DPP4ALDH1A1 | |
| SCHEMBL7415958 | 0.78 | ALOX5AP (0.43) | S1PR3TP53DPP4PPARGALDH1A1 | |
| SCHEMBL7419090 | 0.78 | L3MBTL1 (0.47) | S1PR3MAPTTP53DPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820441-B1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |